Phase 3 THOR Japanese Subgroup Analysis: Erdafitinib in Advanced or Metastatic Urothelial Cancer and Fibroblast Growth Factor Receptor Alterations.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY(2024)
Key words
Erdafitinib,Fibroblast growth factor receptor,Japanese subgroup,Oral tyrosine kinase inhibitor,Metastatic urothelial carcinoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined